Echo Therapeutics PE Ratio 2010-2016 | ECTE
Current and historical p/e ratio for Echo Therapeutics (ECTE) from 2010 to 2016. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Echo Therapeutics PE ratio as of May 02, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Echo Therapeutics PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2021-09-08 | 0.00 | 0.00 | |
| 2016-09-30 | 0.38 | $-1.28 | 0.00 |
| 2016-06-30 | 1.30 | $-1.33 | 0.00 |
| 2016-03-31 | 1.31 | $-1.48 | 0.00 |
| 2015-12-31 | 1.42 | $-1.97 | 0.00 |
| 2015-09-30 | 1.55 | $-1.89 | 0.00 |
| 2015-06-30 | 1.70 | $-2.16 | 0.00 |
| 2015-03-31 | 2.13 | $-1.50 | 0.00 |
| 2014-12-31 | 1.35 | $-1.01 | 0.00 |
| 2014-09-30 | 0.84 | $-1.33 | 0.00 |
| 2014-06-30 | 2.26 | $-1.39 | 0.00 |
| 2014-03-31 | 3.00 | $-1.59 | 0.00 |
| 2013-12-31 | 3.14 | $-2.66 | 0.00 |
| 2013-09-30 | 2.76 | $-2.70 | 0.00 |
| 2013-06-30 | 2.49 | $-3.31 | 0.00 |
| 2013-03-31 | 7.90 | $-3.60 | 0.00 |
| 2012-12-31 | 10.40 | $-3.10 | 0.00 |
| 2012-09-30 | 15.70 | $-4.60 | 0.00 |
| 2012-06-30 | 16.20 | $-3.90 | 0.00 |
| 2012-03-31 | 20.21 | $-3.70 | 0.00 |
| 2011-12-31 | 22.60 | $-4.90 | 0.00 |
| 2011-09-30 | 29.01 | $-3.40 | 0.00 |
| 2011-06-30 | 40.60 | $-3.20 | 0.00 |
| 2011-03-31 | 40.00 | $-2.80 | 0.00 |
| 2010-12-31 | 16.00 | $-1.50 | 0.00 |
| 2010-09-30 | 10.00 | $-1.60 | 0.00 |
| 2010-06-30 | 12.50 | $-1.90 | 0.00 |
| 2010-03-31 | 15.00 | $-6.30 | 0.00 |
| 2009-12-31 | 17.00 | $-6.30 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.000B | $0.000B |
| Echo Therapeutics, Inc., a medical device and specialty pharmaceutical company, develops a non-invasive and wireless transdermal continuous glucose monitoring system for people with diabetes and for use in hospital critical care units in the United States. Its Symphony transdermal continuous glucose monitoring System is a non-invasive, wireless, designed to provide reliable, on-demand blood glucose data conveniently, continuously and cost-effectively. The company is based in Franklin, Massachusetts. | |||